The clinical impact of islet transplantation

被引:176
作者
Fiorina, P. [1 ,2 ]
Shapiro, A. M. J. [3 ]
Ricordi, C. [4 ]
Secchi, A. [1 ,5 ]
机构
[1] Ist Sci San Raffaele, I-20132 Milan, Italy
[2] Harvard Univ, Brigham & Womens Hosp, Sch Med, Childrens Hosp,Transplantat Res Ctr, Boston, MA 02115 USA
[3] Islet Transplantat Ctr, Edmonton, AB, Canada
[4] Diabet Res Inst, Miami, FL USA
[5] Univ Vita Salute San Raffaele, Milan, Italy
关键词
islet transplantation; type 1 diabetes mellitus; immunosuppression; late complications of diabetes;
D O I
10.1111/j.1600-6143.2008.02353.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Islet cell transplantation has recently emerged as one of the most promising therapeutic approaches to improving glycometabolic control in diabetic patients and, in many cases, achieving insulin independence. Unfortunately, many persistent flaws still prevent islet transplantation from becoming the gold standard treatment for type 1 diabetic patients. We review the state of the art of islet transplantation, outcomes, immunosuppression and-most important-the impact on patients' survival and long-term diabetic complications and eventual alternative options. Finally, we review the many problems in the field and the challenges to islet survival after transplantation. The rate of insulin independence 1 year after islet cell transplantation has significantly improved in recent years (60% at 1 year posttransplantation compared with 15% previously). Recent data indicate that restoration of insulin secretion after islet cell transplantation is associated with an improvement in quality of life, with a reduction in hypoglycemic episodes and potentially with a reduction in long-term diabetic complications. Once clinical islet transplantation has been successfully established, this treatment could even be offered to diabetic patients long before the onset of diabetic complications.
引用
收藏
页码:1990 / 1997
页数:8
相关论文
共 39 条
[21]   Searching for glycemic control in pediatric type 1 diabetes: A long way to go [J].
Kaufman, FR .
JOURNAL OF PEDIATRICS, 2001, 139 (02) :174-176
[22]   EFFECTS OF PANCREATIC TRANSPLANTATION ON DIABETIC NEUROPATHY [J].
KENNEDY, WR ;
NAVARRO, X ;
GOETZ, FC ;
SUTHERLAND, DER ;
NAJARIAN, JS .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (15) :1031-1037
[23]   Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes [J].
Keymeulen, B ;
Vandemeulebroucke, E ;
Ziegler, AG ;
Mathieu, C ;
Kaufman, L ;
Hale, G ;
Gorus, F ;
Goldman, M ;
Walter, M ;
Candon, S ;
Schandene, L ;
Crenier, L ;
De Block, C ;
Seigneurin, JM ;
De Pauw, P ;
Pierard, D ;
Weets, I ;
Rebello, P ;
Bird, P ;
Berrie, E ;
Frewin, M ;
Waldmann, H ;
Bach, JF ;
Pipeleers, D ;
Chatenoud, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (25) :2598-2608
[24]   Effects of streptozocin diabetes and diabetes treatment by islet transplantation on in vivo insulin signaling in rat heart [J].
Laviola, L ;
Belsanti, G ;
Davalli, AM ;
Napoli, R ;
Perrini, S ;
Weir, GC ;
Giorgino, R ;
Giorgino, F .
DIABETES, 2001, 50 (12) :2709-2720
[25]   The effect of pancreatic islet transplantation on progression of diabetic retinopathy and neuropathy [J].
Lee, TC ;
Barshes, NR ;
O'Mahony, CA ;
Nguyen, L ;
Brunicardi, FC ;
Ricordi, C ;
Alejandro, R ;
Schock, AP ;
Mote, A ;
Goss, JA .
TRANSPLANTATION PROCEEDINGS, 2005, 37 (05) :2263-2265
[26]   A novel mechanism of action for anti-thymocyte globulin:: Induction of CD4+CD25+Foxp3+ regulatory T cells [J].
Lopez, Marta ;
Clarkson, Michael R. ;
Albin, Monica ;
Sayegh, Mohamed H. ;
Najafian, Nader .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (10) :2844-2853
[27]   Metabolic effects of successful intraportal islet transplantation in insulin-dependent diabetes mellitus [J].
Luzi, L ;
Hering, BJ ;
Socci, C ;
Raptis, G ;
Battezzati, A ;
Terruzzi, I ;
Falqui, L ;
Brandhorst, H ;
Brandhorst, D ;
Regalia, E ;
Brambilla, E ;
Secchi, A ;
Perseghin, G ;
Maffi, P ;
Bianchi, E ;
Mazzaferro, V ;
Gennari, L ;
DiCarlo, V ;
Federlin, K ;
Pozza, G ;
Bretzel, RG .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (11) :2611-2618
[28]   Metabolic effects of restoring partial β-cell function after islet allotransplantation in type 1 diabetic patients [J].
Luzi, L ;
Perseghin, G ;
Brendel, MD ;
Terruzzi, I ;
Battezzati, A ;
Eckhard, M ;
Brandhorst, D ;
Brandhorst, H ;
Friemann, S ;
Socci, C ;
Di Carlo, V ;
Sereni, LP ;
Benedini, S ;
Secchi, A ;
Pozza, G ;
Bretzel, RG .
DIABETES, 2001, 50 (02) :277-282
[29]   Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-Cells [J].
Monti, Paolo ;
Scirpoli, Miriam ;
Maffi, Paola ;
Piemonti, Lorenzo ;
Secchi, Antonio ;
Bonifacio, Ezio ;
Roncarolo, Maria-Grazia ;
Battaglia, Manuela .
DIABETES, 2008, 57 (09) :2341-2347
[30]   β-cell function following human islet transplantation for type 1 diabetes [J].
Rickels, MR ;
Schutta, MH ;
Markmann, JF ;
Barker, CF ;
Naji, A ;
Teff, KL .
DIABETES, 2005, 54 (01) :100-106